Can the pharmaceutical industry reduce attrition rates? (original) (raw)

Nature Reviews Drug Discovery volume 3, pages 711–716 (2004)Cite this article

Abstract

The pharmaceutical industry faces considerable challenges, both politically and fiscally. Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny. In the United States, drug costs are also the subject of intense political discourse. This article deals with the fiscal pressures that face the industry from the perspective of R&D. What impinges on productivity? How can we improve current reduced R&D productivity?

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
  2. Franz, S. 2003 approvals: a year of innovation and upward trends. Nature Rev. Drug Discov. 3, 103–105 (2004).
    Article Google Scholar
  3. Accenture Consulting. High performance drug discovery: an operating model for a new era. Accenture (2001).
  4. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).
    Article Google Scholar
  5. Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
    Google Scholar
  6. Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nature Rev. Drug Discov. 2, 609–610 (2003).
    Article CAS Google Scholar
  7. Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
    Google Scholar
  8. Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
    Google Scholar
  9. Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001).
    Article CAS Google Scholar
  10. Gowen, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654–1663 (1999).
    Article CAS Google Scholar
  11. Lazner, F., Gowen, M. & Kola, I. An animal model for pycnodysostosis: the role of cathepsin K in bone remodeling. Mol. Med. Today 5, 413–414 (1999).
    Article CAS Google Scholar
  12. Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571–572 (2002).
    Article CAS Google Scholar

Download references

Acknowledgements

We wish to acknowledge Datamonitor for the assembly of data (Pharmaceutical R&D Benchmarking Forum) used in this study.

Author information

Authors and Affiliations

  1. Senior Vice-President of Basic Research at Merck Research Labs, 126 East Lincoln Avenue, Rahway, 07075, New Jersey, USA
    Ismail Kola Ph.D. (Med)
  2. Senior Vice-President, Pharmaceutical Sciences and Compliance Clinical Sciences at Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, 07033, New Jersey, USA
    John Landis Ph.D.

Authors

  1. Ismail Kola Ph.D. (Med)
    You can also search for this author inPubMed Google Scholar
  2. John Landis Ph.D.
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toIsmail Kola Ph.D. (Med).

Ethics declarations

Competing interests

I.K. is an employee of Merck & Co., Inc., and has financial interests in Merck, Pfizer Inc. and Schering-Plough Corp. J.L. is an employee of Schering-Plough Corp. and has financial interests in Schering-Plough and Pfizer Inc.

FURTHER INFORMATION

PhRMA

Rights and permissions

About this article

Cite this article

Kola, I., Landis, J. Can the pharmaceutical industry reduce attrition rates?.Nat Rev Drug Discov 3, 711–716 (2004). https://doi.org/10.1038/nrd1470

Download citation

This article is cited by